Uncategorized

Bristol-Myers plans to divest Celgene’s psoriasis drug

Spread the love

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Read More Original Article Here